The company said revenue for the first quarter ended January 31, 2024 was $1.66 billion, down 5.6% from a year earlier (down 6.4% on a core basis). GAAP net income was $348 million, and diluted earnings per share were $1.18.

1. 01

   The company said revenue for the first quarter ended January 31, 2024 was $1.66 billion, down 5.6% from a year earlier (down 6.4% on a core basis). GAAP net income was $348 million, and diluted earnings per share were $1.18.

2. 02

   The company said revenue for Q1 at Life Sciences and Applied Markets Group was $846 million, down 10% (operating margin of 27.9%). Agilent CrossLab Group revenue was $405 million, up 6% (30.2%), and Diagnostics and Genomics Group revenue was $407 million, down 6% (17.3%).

3. 03

   Agilent said it maintained its full-year revenue outlook at $6.710 billion to $6.810 billion and its non-GAAP earnings per share outlook at $5.44 to $5.55. It projected second-quarter revenue of $1.560 billion to $1.590 billion and non-GAAP earnings per share of $1.17 to $1.20 for Q2.

4. 04

   The company reported net cash provided by operating activities of $485 million for the 3 months ($296 million a year earlier) and said it repaid $180 million of long-term debt during the period. Cash and cash equivalents were $1,748 million as of January 31, 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.